Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 17, 2012 - Issue 3
Submit an article Journal homepage
1,195
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Emerging biological insights and novel treatment strategies in multiple myeloma

Massimo GentileUnità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy+39 0 984 681329; +39 0 984 791751; [email protected]
,
Anna Grazia RecchiaUnità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy+39 0 984 681329; +39 0 984 791751; [email protected]
,
Carla MazzoneUnità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy+39 0 984 681329; +39 0 984 791751; [email protected]
&
Fortunato MorabitoUnità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy+39 0 984 681329; +39 0 984 791751; [email protected]
Pages 407-438 | Published online: 27 Aug 2012

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Xiao Liu, Chengyuan Li, Yunfeng Fu & Jing Liu. (2020) PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2. OncoTargets and Therapy 13, pages 401-411.
Read now
Barbara Muz, Rachel Nicole Ghazarian, Monica Ou, Micah John Luderer, Hubert Daniel Kusdono & Abdel Kareem Azab. (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Design, Development and Therapy 10, pages 217-226.
Read now
Philippe Moreau. (2014) The emerging role of carfilzomib combination therapy in the management of multiple myeloma. Expert Review of Hematology 7:2, pages 265-290.
Read now

Articles from other publishers (8)

Yarasani Prashanthi, Faheem Ahmed, Tentu Nageswara Rao & Botsa Parvatamma. (2021) METHOD DEVELOPMENT AND VALIDATION OF IXAZOMIB DRUG BY RP-HPLC IN BULK AND PHARMACEUTICAL DOSAGE FORM. INDIAN DRUGS 58:01, pages 28-34.
Crossref
Kejie Zhang, Aakash Desai, Dongfeng Zeng, Tiejun Gong, Peihua Lu & Michael Wang. (2016) Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 8:6, pages 10748-10759.
Crossref
Don RobinsonJrJr, Dixie‐Lee Esseltine, Antoine Regnault, Juliette Meunier, Kevin Liu & Helgi Velde. (2016) The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials. British Journal of Haematology 174:3, pages 368-381.
Crossref
Virginie Follin-Arbelet, Kristine Misund, Elin Hallan Naderi, Hege Ugland, Anders Sundan & Heidi Kiil Blomhoff. (2015) The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. Scientific Reports 5:1.
Crossref
Nassera Aouali, Angeliki Broukou, Manon Bosseler, Olivier Keunen, Vincent Schlesser, Bassam Janji, Valerie Palissot, Philippe Stordeur & Guy Berchem. (2015) Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells. PLOS ONE 10:6, pages e0130339.
Crossref
Swaminathan P. Iyer, Joseph Taddeus Beck, A. Keith Stewart, Jatin Shah, Kevin R. Kelly, Randi Isaacs, Sanela Bilic, Suman Sen & Nikhil C. Munshi. (2014) A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events . British Journal of Haematology 167:3, pages 366-375.
Crossref
Shaji K. KumarWilliam I. BensingerTodd M. ZimmermanCraig B. ReederJames R. BerensonDeborah BergAi-Min HuiNeeraj GuptaAlessandra Di BaccoJiang YuYaping ShouRuben Niesvizky. (2014) Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 124:7, pages 1047-1055.
Crossref
. 2014. Primer to the Immune Response. Primer to the Immune Response 553 585 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.